Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 5 de 5
Filter
Add more filters










Database
Language
Publication year range
1.
Sci Rep ; 13(1): 11318, 2023 07 13.
Article in English | MEDLINE | ID: mdl-37443134

ABSTRACT

Cardiac autonomic neuropathy (CAN), widely assessed by heart rate variability (HRV), is a common complication of long-term diabetes. We hypothesized that HRV dynamics during tonic cold pain in individuals with type 1 diabetes mellitus (T1DM) could potentially demask CAN. Forty-eight individuals with long-term T1DM and distal symmetrical polyneuropathy and 21 healthy controls were included. HRV measures were retrieved from 24-h electrocardiograms. Moreover, ultra-short-term HRV recordings were used to assess the dynamic response to the immersion of the hand into 2 °C cold water for 120 s. Compared to healthy, the T1DM group had expectedly lower 24-h HRV measures for most components (p < 0.01), indicating dysautonomia. In the T1DM group, exposure to cold pain caused diminished sympathetic (p < 0.001) and adynamic parasympathetic (p < 0.01) HRV responses. Furthermore, compared to healthy, cold pain exposure caused lower parasympathetic (RMSSD: 4% vs. 20%; p = 0.002) and sympathetic responses (LF: 11% vs. 73%; p = 0.044) in the T1MD group. QRISK3-scores are negatively correlated with HRV measures in 24-h and ultra-short-term recordings. In T1DM, an attenuated sympathovagal response was shown as convincingly adynamic parasympathetic responses and diminished sympathetic adaptability, causing chronometric heart rhythm and rigid neurocardiac regulation threatening homeostasis. The findings associate with an increased risk of cardiovascular disease, emphasizing clinical relevance.


Subject(s)
Diabetes Mellitus, Type 1 , Polyneuropathies , Primary Dysautonomias , Humans , Diabetes Mellitus, Type 1/complications , Autonomic Nervous System/physiology , Heart , Primary Dysautonomias/etiology , Heart Rate/physiology
2.
J Ocul Pharmacol Ther ; 38(1): 114-121, 2022.
Article in English | MEDLINE | ID: mdl-34918951

ABSTRACT

Purpose: Liraglutide treatment has shown promising anti-inflammatory and nerve regenerative results in preclinical and clinical trials. We sought to assess if liraglutide treatment would induce nerve regeneration through its anti-inflammatory and neurotrophic mechanisms by increasing peripapillary retinal nerve fiber layer (RNFL) thickness in individuals with long-term type 1 diabetes. Methods: Secondary analyses were performed on a prospective, double-blinded, randomized, placebo-controlled trial on adults with type 1 diabetes, distal symmetric polyneuropathy (DSPN), and confirmed diabetic retinopathy, who were randomized 1:1 to either 26 weeks placebo or liraglutide treatment. The primary endpoint was a change in peripapillary RNFL thickness between treatments, assessed by optical coherence tomography. Results: Thirty-seven participants were included in the secondary analysis. No differences in mean peripapillary RNFL thickness (overall ΔMean RNFL thickness; liraglutide -1 (±8) µm (-1%) vs. placebo -1 (±5) µm (-1%), P = 0.78, n = 37) or any of the quadrants. Peripapillary RNFL thicknesses were shown between treatments in either nonproliferative (ΔMean RNFL thickness; liraglutide -1 (±5) µm (-1%) vs. placebo 0 (±4) µm (0%), P = 0.80, N = 26) or proliferative diabetic retinopathy subgroup (ΔMean RNFL thickness; liraglutide -2 (±14) µm (-3%) vs. placebo -1 (±6) µm (-2%), P = 0.88, N = 11). Conclusions: In this study, 26 weeks of liraglutide treatment did not induce measurable changes in the assessed optic nerve thickness. Thus, this methodology does not support the induction of substantial nerve regeneration in this cohort with established retinopathy and DSPN. The trial was approved by the Danish Health and Medicines Authority. Informed consent was obtained from all participants. TODINELI study: EUDRA CT: 2013-004375-12, Ethics Ref: N-20130077 Clinical trial registration number: clinicaltrials.gov NCT02138045.


Subject(s)
Diabetic Retinopathy/pathology , Liraglutide/pharmacology , Nerve Fibers/drug effects , Retina/drug effects , Adult , Diabetes Mellitus, Type 1/pathology , Double-Blind Method , Female , Humans , Male , Middle Aged , Prospective Studies , Tomography, Optical Coherence
3.
Scand J Pain ; 17: 260-266, 2017 10.
Article in English | MEDLINE | ID: mdl-29229212

ABSTRACT

BACKGROUND AND PURPOSE: Acid has long been thought to play an important role in the pain process. Animal study showed that repeated acid stimulation induced central sensitization. The purpose of the study is to investigate muscle pain and hyperalgesia evoked by intramuscular infusion of saline at different pH levels, and to compare the effect of a single versus repeated acid infusions. METHODS: Twenty healthy subjects received infusions of buffered saline (pH 5.0, 6.0, and 7.4) into the brachioradialis muscle in a randomized order. Twelve of the subjects received repeated infusions. The subjects rated the pain intensity on visual analogue scale (VAS). Thermal pain sensitivity, and pressure pain threshold (PPT) were assessed in both arm before, during, immediately after, one hour after, and one day after the infusion. A McGill Pain Questionnaire and pain mapping were completed after each infusion. RESULTS: The pH 5 solution caused significantly higher pain and larger areas than pH 6.0 or 7.4. The local PPTs were significantly decreased (hyperalgesia) during and immediately after infusion of all three solutions. No significant differences were detected between the first and second infusion. CONCLUSIONS: The intensity of acid-induced muscle pain is pH-dependent. All three solutions induced pressure hyperalgesia at the infusion site. Repeated infusions did not induce increased pain or prolonged hyperalgesia as compared with a single injection. Human intramuscular acidic saline infusion could not produce chronic pain model. IMPLICATIONS: The acid-induced pain model may reflect the early stage responses to tissue injury of clinical conditions. Repeated intramuscular acidic saline injection model of prolonged hyperalgesia in rodents could not be translated into a human for modelling chronic musculoskeletal pain.


Subject(s)
Acids , Forearm , Hyperalgesia/chemically induced , Injections, Intramuscular/methods , Myalgia , Saline Solution/administration & dosage , Female , Humans , Male , Pain Measurement/methods , Pain Threshold , Sex Factors , Young Adult
4.
Nicotine Tob Res ; 18(5): 596-603, 2016 May.
Article in English | MEDLINE | ID: mdl-26242288

ABSTRACT

INTRODUCTION: This study implemented an intra-oral test-platform to assess the sensory, psychophysical, and vasomotor responses to nicotine and menthol, alone or in combination. METHODS: Two double-blinded, placebo-controlled, randomized, cross-over studies, including healthy nonsmoking participants were performed. Study I: A dose-response relationship (N = 20) between 0, 2, and 4 mg nicotine gum. Study II: An interaction response (N = 22) to 30 mg menthol and 4 mg nicotine alone or in combination. Heart rate, blood pressure, tactile and thermosensory thresholds, intra-oral blood flow and temperature, pain/irritation intensities/locations, McGill Pain Questionnaire, and taste experience were assessed before, during or after the completion of a standardized chewing regime. RESULTS: A dose-response elevation in heart rate was attenuated when nicotine was combined with menthol. Blood flow, temperature, and warm-detection thresholds, as assessed on the tongue, similarly increased for all gums. Pain intensity and taste experiences were similar between nicotine doses. Nicotine attenuated the sweet, cooling, and freshening sensation of menthol. Within the first 4 minutes, menthol reduced the intensity but not the area of nicotine-induced pain and irritation. The 4-mg nicotine dose led to a continued increase in the intensity and area of irritation in the throat post-chewing. Moreover, one-half of participants responded to menthol as an irritant, and these individuals demonstrated larger areas of nicotine-induced irritation in the throat post-chewing. CONCLUSIONS: The intra-oral test platform provides a basis to optimize the assessment of nicotine-related taste and sensory experiences and can be used in future studies for profiling nicotine gum.


Subject(s)
Blood Pressure/drug effects , Heart Rate/drug effects , Menthol/administration & dosage , Mouth/drug effects , Nicotine/administration & dosage , Thermosensing/drug effects , Tobacco Use Cessation Devices , Adult , Cross-Over Studies , Dose-Response Relationship, Drug , Double-Blind Method , Drug Interactions , Female , Humans , Irritants , Male , Menthol/adverse effects , Mouth/blood supply , Nicotine/adverse effects , Pain/chemically induced , Pain Measurement , Pharynx/drug effects , Regional Blood Flow/drug effects , Tobacco Use Cessation Devices/adverse effects , Tongue/blood supply , Tongue/drug effects , Young Adult
5.
Br J Clin Pharmacol ; 76(6): 951-63, 2013 Dec.
Article in English | MEDLINE | ID: mdl-23521205

ABSTRACT

AIMS: To compare results from analysis of averaged and single-sweep evoked brain potentials (EPs) by visual inspection and spectral analysis in order to identify an objective measure for the analgesic effect of buprenorphine and fentanyl. METHODS: Twenty-two healthy males were included in a randomized study to assess the changes in EPs after 110 sweeps of painful electrical stimulation to the median nerve following treatment with buprenorphine, fentanyl or placebo patches. Bone pressure, cutaneous heat and electrical pain ratings were assessed. EPs and pain assessments were obtained before drug administration, 24, 48, 72 and 144 h after beginning of treatment. Features from EPs were extracted by three different approaches: (i) visual inspection of amplitude and latency of the main peaks in the average EPs, (ii) spectral distribution of the average EPs and (iii) spectral distribution of the EPs from single-sweeps. RESULTS: Visual inspection revealed no difference between active treatments and placebo (all P > 0.05). Spectral distribution of the averaged potentials showed a decrease in the beta (12-32 Hz) band for fentanyl (P = 0.036), which however did not correlate with pain ratings. Spectral distribution in the single-sweep EPs revealed significant increases in the theta, alpha and beta bands for buprenorphine (all P < 0.05) as well as theta band increase for fentanyl (P = 0.05). For buprenorphine, beta band activity correlated with bone pressure and cutaneous heat pain (both P = 0.04, r = 0.90). CONCLUSION: In conclusion single-sweep spectral band analysis increases the information on the response of the brain to opioids and may be used to identify the response to analgesics.


Subject(s)
Analgesics, Opioid/pharmacology , Brain/drug effects , Buprenorphine/pharmacology , Electroencephalography/drug effects , Evoked Potentials/drug effects , Fentanyl/pharmacology , Adult , Analgesics, Opioid/administration & dosage , Analgesics, Opioid/therapeutic use , Brain/physiopathology , Buprenorphine/administration & dosage , Buprenorphine/therapeutic use , Cross-Over Studies , Data Interpretation, Statistical , Double-Blind Method , Electric Stimulation , Evoked Potentials/physiology , Fentanyl/administration & dosage , Fentanyl/therapeutic use , Healthy Volunteers , Humans , Male , Pain/drug therapy , Pain/physiopathology , Pain Measurement , Transdermal Patch , Young Adult
SELECTION OF CITATIONS
SEARCH DETAIL
...